2022
DOI: 10.3389/fonc.2022.1030798
|View full text |Cite
|
Sign up to set email alerts
|

The efficacy and safety of Apatinib in the treatment of advanced non-small cell lung cancer: A retrospective trial

Abstract: BackgroundAs a potent inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway, Apatinib has been used in antitumor treatment for some time. The study aimed to research the therapeutic effects and toxicity of Apatinib in the treatment of advanced non-small cell lung cancer (NSCLC).MethodsWe retrospectively analyzed 128 NSCLC patients treated with Apatinib in Qilu Hospital of Shandong University. Response Evaluation Criteria in Solid Tumors (RECIST) criteria was adopted to evaluate the treat… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 26 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?